Aligos Therapeutics, Inc.
ALGS • NASDAQ
Aligos Therapeutics, Inc. is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Lawrence Blatt, with a market cap of $41.2M.
CEOLawrence Blatt
Next Earnings
Upcoming earnings announcement for Aligos Therapeutics, Inc.
Date
Tuesday, May 5, 2026 (in a month)
Timing
Before Market Open (8:00 AM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$2.29
Revenue Estimate
$333.3K
Earnings History
Past 12 earnings reports for Aligos Therapeutics, Inc.
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 5, 2026 | Q4 2025 | -$1.91Est: -$2.33 | +18.0% | $169.0KEst: $266.7K | -36.6% |  10-K |
| Nov 6, 2025 | Q3 2025 | -$3.04Est: -$2.04 | -49.0% | $741.0KEst: $500.0K | +48.2% | 10-Q |
| Aug 6, 2025 | Q2 2025 | -$1.53Est: -$2.46 | +37.8% | $965.0KEst: $660.0K | +46.2% | 10-Q |
| May 6, 2025 | Q1 2025 | -$2.11Est: -$3.15 | +33.0% | $311.0KEst: $500.0K | -37.8% | 10-Q |
| Mar 10, 2025 | Q4 2024 | -$13.08Est: -$3.67 | -256.4% | $629.0KEst: $433.3K | +45.2% | 10-K |
| Nov 6, 2024 | Q3 2024 | -$3.07Est: -$2.16 | -42.1% | $1.3MEst: $330.0K | +284.5% | 10-Q |
| Aug 6, 2024 | Q2 2024 | $0.75Est: -$4.00 | +118.8% | $1.1M | — | 10-Q |
| May 7, 2024 | Q1 2024 | -$5.50Est: -$4.75 | -15.8% | $986.0K | — | 10-Q |
| Mar 12, 2024 | Q4 2023 | -$5.50Est: -$6.75 | +18.5% | $2.0MEst: $1.6M | +25.6% | 10-K |
| Nov 2, 2023 | Q3 2023 | -$10.25Est: -$11.75 | +12.8% | $2.2MEst: $2.5M | -13.8% | — |
| Aug 3, 2023 | Q2 2023 | -$10.75Est: -$12.25 | +12.2% | $2.6M | — | 10-Q |
| May 4, 2023 | Q1 2023 | -$13.25Est: -$12.00 | -10.4% | $2.7M | — | — |